NurExone Biologic
Business Services · Israel · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Minus 1 Entry Ground Floor of Building B...Phone Number
+972524803034Website
www.nurexone.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About NurExone Biologic
NurExone is a biotechnology company focused on developing innovative exosome-based therapies for acute spinal cord injury and glaucoma, addressing significant unmet medical needs in these areas. Their ExoTherapy platform utilizes nanosized extracellular vesicles to deliver therapeutic compounds, promoting regeneration and recovery in damaged tissues. With a commitment to minimal invasiveness and effective drug delivery, NurExone aims to revolutionize treatment options for patients. The company is positioned to tap into multi-billion dollar global markets, with a dedicated team and proprietary technology driving their research and development efforts.Explore more
NurExone Biologic Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is NurExone Biologic your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once NurExone Biologic has new funding data
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on NurExone Biologic recently announced quarterly report
Click to see if NurExone Biologic had a recent Job posting/layoffs
Check out if NurExone Biologic is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
NurExone Biologic, which may be a good buyer, showed buying intent in Masked Content Topic
Check if NurExone Biologic has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when NurExone Biologic launches new products
Congratulate Masked Content for being promoted to Masked Content at NurExone Biologic
Recommended Actions
Reach out to Masked Content who joined NurExone Biologic as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
NurExone Biologic is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
NurExone Biologic is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about NurExone Biologic.
NurExone Biologic financials insights
Gather financial insights about NurExone Biologic, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2025
Stock/Share Issuance
$148K
2026
Stock/Share Issuance
$280K
Stock/Share Issuance
$451K
NurExone Biologic Tech Stack
A closer look at the technologies used by NurExone Biologic
See more technologies
Most Recent Scoops
Funding
Funding
Person-Based
Medical Research
Person-Based
Product Development, Research & Development, Clinical Operations
Earnings
Earnings, Finance
Earnings
Earnings, Finance
NurExone Biologic News & Media
NurExone Biologic Inc. Announces Second Quarter 2026 Financial Results
TORONTO and HAIFA, Israel, Aug. 31, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biotechnology company developing exosome-based regenerative therapies, is pleased to announce its financial results for the second quarter ended June 30, 2026 (“Q2”), and to provide a corporate update on its recent activities and upcoming milestones.NurExone Biologic Inc. to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference
TORONTO and HAIFA, Israel, Aug. 28, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biotechnology company developing exosome-based regenerative therapies, today announced that it is scheduled to participate in the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference, taking place September 9–10, 2026, in New York City.NurExone Announces Annual General and Special Meeting to Consider Share Consolidation in Support of U.S. Capital Markets Strategy
Proposed share consolidation of up to 30:1 intended to support potential U.S. exchange listing and broaden investor appealNurExone Announces Closing of C$1,066,078 Private Placement
TORONTO, and HAIFA, Israel, Aug. 21, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce that it has closed a non-brokered private placement of 1,938,326 units (“Units”) at a price of C$0.55 per Unit for aggregate gross proceeds of approximately C$1,066,078.02 (the “Offering”), subject to final acceptance of the TSX Venture Exchange
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding NurExone Biologic
Sign Up For FreeTo access detailed company insights
NurExone is a biotechnology company focused on developing innovative exosome-based therapies for acute spinal cord injury and glaucoma, addressing significant unmet medical needs in these areas. Their ExoTherapy platform utilizes nanosized extracellular vesicles to deliver therapeutic compounds, promoting regeneration and recovery in damaged tissue... Read More
